Design Therapeutics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-03-30

Reporting Person: George Simeon (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	4439839	—	Acquired	4439839	Indirect
2021-03-30	Common Stock	C	936637	—	Acquired	5376476	Indirect
2021-03-30	Common Stock	P	250000	$20.00	Acquired	5626476	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series A Preferred Stock	$	C	7236938	Disposed		Common Stock (4439839)	Indirect
2021-03-30	Series B Preferred Stock	$	C	1526718	Disposed		Common Stock (936637)	Indirect

Footnotes

F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2: The reported securities are held directly by SR One Capital Fund I Aggregator, LP. SR One Capital Partners I, LP is the general partner of SR One Capital Fund I Aggregator, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners I, LP, SR One Capital Management, LLC and Mr. George may each be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

F3: The shares were purchased in the Issuer's initial public offering.